Intracranial self-stimulation (ICSS) is an operant procedure in which responding is maintained by electrical brain stimulation. Stimulation frequency can be varied rapidly to maintain a wide range of baseline response rates, and drugs' effects can be evaluated simultaneously on both low ICSS rates maintained by low stimulation frequencies and high ICSS rates maintained by high stimulation frequencies. ICSS 'facilitation' indicates drug-induced increases in low ICSS rates and is often considered an abuse-related effect, whereas ICSS 'depression' indicates decreases in high ICSS rates and may indicate abuselimiting effects. This study examined the roles of l-agonist efficacy and of previous l-agonist exposure as determinants of l-agonist effects on ICSS in rats with electrodes implanted into the medial forebrain bundle. The high-efficacy, intermediate-efficacy, and low-efficacy l agonists methadone, fentanyl, and nalbuphine were tested during escalating regimens of morphine exposure (vehicle, 3.2, and 18 mg/kg/day). During vehicle treatment, methadone and fentanyl primarily depressed ICSS, whereas nalbuphine produced weak facilitation that was not dose dependent. Chronic morphine produced tolerance to ICSS depression and increased expression of ICSS facilitation. These results suggest that l-agonist exposure increases the expression of abuse-related ICSS facilitation by l agonists with a broad range of efficacies at l receptors.
Introduction m-Opioid receptor agonists constitute one class of medications that are used extensively in the clinic for their analgesic properties. One limitation on their use is their abuse potential (Cicero et al., 2007; Denisco et al., 2008) . Multiple preclinical procedures have been developed to examine abuse-related effects of opioids, one of which is intracranial self-stimulation (ICSS) (Kornetsky et al., 1979; Wise, 1998) . ICSS is an operant procedure in which experimental animals learn to self-administer brief electrical pulses into brain regions that are considered to be part of the brain's reward pathways. The frequency of electrical stimulation can be varied rapidly to manipulate the magnitude of reinforcement and to maintain a wide range of baseline response rates. Drug effects can then be efficiently evaluated on both low ICSS rates maintained by low stimulation frequencies and high ICSS rates maintained by high stimulation frequencies. ICSS 'facilitation' denotes drug-induced increases in low ICSS rates and is often interpreted as an abuse-related effect, whereas ICSS 'depression' denotes decreases in high ICSS rates and may be indicative of abuse-limiting effects (Miliaressis et al., 1986; Carlezon and Chartoff, 2007; Vlachou and Markou, 2010; Altarifi and Negus, 2011; Bauer et al., 2013) . Evaluation of the variables that are involved in opioid-induced changes in ICSS may contribute toward improved understanding of opioid mechanisms in reward and motivation. Accordingly, the aim of the present study was to extend our previous research on determinants of m-opioid agonists on ICSS in rats (Altarifi and Negus, 2011; Altarifi et al., 2012) . Specifically, our previous studies identified two general phenomena: first, the effects of m agonists on ICSS in subjects with no previous history of opioid exposure were dependent on the efficacy of the opioid at m receptors [with in-vitro efficacy to stimulate GTPgS binding as the metric of efficacy (Selley et al., 1998) ]. High-efficacy to intermediate-efficacy m agonists such as methadone and morphine produced biphasic effects that included weak ICSS facilitation, manifested as increases in low ICSS rates maintained by some low brain stimulation frequencies, and robust ICSS depression, manifested as decreases in high ICSS rates maintained by high brain stimulation frequencies. In contrast, lower efficacy m agonists such as nalbuphine were less effective and reliable in producing both rate-increasing and ratedecreasing effects, and the opioid antagonist naltrexone did not alter ICSS at doses that blocked the effects of m agonists. Second, with morphine, chronic treatment produced tolerance to rate-decreasing effects and enhanced expression of rate-increasing effects (Altarifi et al., 2012) . Taken together, these findings suggest that abuse liability of high-efficacy m agonists may be constrained by abuselimiting effects in opioid-naive subjects, but regimens of opioid exposure may produce tolerance to abuse-limiting effects and enhanced expression of abuse-related effects.
The present study examined the interaction between these two phenomena by evaluating the effects of chronic morphine exposure on changes in ICSS produced by four m-opioid receptor ligands that vary in efficacy at m receptors: the high-efficacy m agonist methadone, the intermediate efficacy m agonist fentanyl, the low-efficacy m agonist nalbuphine, and the m antagonist naltrexone (Selley et al., 1998) . We hypothesized that chronic morphine would produce (a) tolerance to ICSS depression and enhanced expression of ICSS facilitation by the high-efficacy m agonists methadone and fentanyl, and (b) dependence as indicated by the emergence of withdrawal-associated ICSS depression by naltrexone. The impact of opioid exposure on ICSS effects of nalbuphine was more difficult to predict, but studies on other behavioral endpoints suggest that chronic treatment with higher efficacy m agonists can produce tolerance to agonist effects and sufficient levels of opioid dependence to expose the antagonist effects of nalbuphine (Woods and Gmerek, 1985; Preston et al., 1989; Oliveto et al., 1991; Young et al., 1991a Young et al., , 1991b .
Methods

Subjects and intracranial self-stimulation electrode implantation
Male Sprague-Dawley rats (Harlan, Frederick, Maryland, USA) weighing 310-350 g at the time of surgery were used for these studies. Rats were housed individually and maintained on a 12-h light/dark cycle with lights on from 06:00 to 18:00 h. Rats had free access to food and water, except during testing. Animal maintenance and research were in compliance with National Institutes of Health guidelines on care and use of animal subjects in research, and all animal use protocols were approved by the Virginia Commonwealth University Institutional Care and Use Committee.
Rats were anesthetized with isoflurane gas (2.5-3% in oxygen; Webster Veterinary, Phoenix, Arizona, USA) for the implantation of stainless-steel electrodes. The cathode of each bipolar electrode (Plastics One, Roanoke, Virginia, USA) was 0.25 mm in diameter and covered with polyamide insulation, except at the flattened tip. The anode was 0.124 mm in diameter and uninsulated. The cathode was implanted into the left medial forebrain bundle at the level of the lateral hypothalamus (2.8 mm posterior and 1.7 mm lateral from the bregma, and 8.8 mm below the skull). The anode was wrapped around one of three skull screws to serve as the ground and the skull screws and electrode assembly were secured with orthodontic resin. Animals were allowed to recover for at least 7 days before commencing ICSS training.
Experimental procedure Apparatus and training
Experiments were conducted in sound-attenuating chambers that contained modular acrylic test chambers (29.2 Â 30.5 Â 24.1 cm) equipped with a response lever (4.5 cm wide, extended 2.0 cm through the center of one wall, 3 cm off the floor), stimulus lights (three lights colored red, yellow and green positioned 7.6 cm directly above the lever), a 2-W white house light, and an ICSS stimulator (Med Associates, St Albans, Vermont, USA). Electrodes were connected to the stimulator through bipolar cables and a commutator (Model SL2C; Plastics One). A computer and software (Med Associates) controlled the stimulator, programming parameters, and data collection.
Rats were trained under a continuous reinforcement schedule of brain stimulation using procedures identical to those described previously (Altarifi and Negus, 2011; Altarifi et al., 2012) . Each lever press resulted in the delivery of a 0.5-s train of square wave cathodal pulses (0.1-ms pulse duration), and stimulation was accompanied by illumination of the stimulus lights above the lever. Responses during the 0.5-s stimulation period did not result in additional stimulation. During the initial phase of training, sessions lasted 30-60 min, the frequency of stimulation was maintained at 158 Hz, and the stimulation intensity was adjusted to the lowest value that would sustain at least 30 stimulations/min. Once this criterion was fulfilled, frequency manipulations were introduced during sessions that consisted of sequential 10-min components. During each component, a descending series of 10 current frequencies (158-56 Hz in 0.05 log increments) was presented, with a 60-s trial at each frequency. A frequency trial began with a 5-s timeout, followed by a 5-s 'priming' phase during which animals received five noncontingent stimulations with a 0.5-s interval between each stimulation. This noncontingent stimulation was followed by a 50-s 'response' phase, during which responding produced electrical stimulation under a continuous reinforcement schedule. Training continued with three to 12 sequential components per day, and the current intensity was adjusted until rats reliably responded during the first three to four frequency trials of all components for at least 3 consecutive days. This intensity (range: 110-220 mA) was held constant for the rest of the study. In addition, rats were habituated to saline injections until these injections had no effect on ICSS frequency-rate curves as determined by two-way analysis of variance (ANOVA) (see the Data analysis section).
ICSS performance before administration of any m agonists. Each predrug baseline session consisted of three components as described above. Rats were then distributed into three different groups. Each group received a different test drug (methadone 0.032-5.6 mg/kg; fentanyl 0.003-0.1 mg/kg; or nalbuphine 0.1-10 mg/kg). Testing in each group proceeded in three phases to evaluate test drug effects before chronic morphine (phase 1), during daily treatment with 3.2 mg/kg/day morphine (phase 2), and during treatment with 18 mg/kg/day morphine (phase 3). In addition to being tested with their designated test m agonist during each phase, all rats were also tested with 0.1 mg/kg naltrexone after m agonist testing during phase 3. Rats in the methadone and nalbuphine groups were also tested again 3 weeks after termination of repeated morphine (phase 4). Table 1 summarizes the sequence of treatments in all groups.
The first phase started immediately after the third predrug baseline session and lasted for 15-20 days. Daily ICSS sessions in this and all subsequent phases consisted of (a) three consecutive daily-baseline components, (b) a 30 min timeout, with administration of saline or drug at the beginning of the timeout, and (c) two more test components. Thus, ICSS was assessed twice each day: once during the daily-baseline components before that day's injection of saline or drug (and B23 h after the previous day's injection) and once during the test components that began 30 min after that day's injection. After the last component, subjects were removed from the test chamber and returned to their home cages. Test sessions involving the administration of active doses of the test drug were separated by at least 3 days in the fentanyl group, which was the first group studied. A modification of the experimental design was introduced for the later methadone and nalbuphine groups (see below for rationale), and in these groups, test sessions with active doses were separated by at least 2 days. For all groups, saline was administered instead of the test drug on intervening days. ICSS sessions were sometimes omitted on weekends.
The second phase started with a 7-day maintenance period, during which 3.2 mg/kg/day morphine was administered during the timeout of each daily ICSS session. On day 8, test sessions were resumed, and test drug effects were redetermined using the same dose order and intervals as the first phase. In addition, the fentanyl group was also tested with an additional higher dose in phase 2 after testing with the original doses was completed. On the days that subjects did not receive test drug, they received 3.2 mg/kg morphine. This morphine injection was usually administered during the timeout of an ICSS session as described above; however, ICSS sessions were occasionally omitted during the weekends, and on these days, the morphine injection was administered without ICSS. As in phase 1, test sessions for fentanyl were separated by at least 3 days, so that each test session was preceded by at least 2 days of treatment with the chronic morphine dose. In the methadone and nalbuphine groups, an alternative design was implemented to minimize protracted opioid withdrawal on days when saline or low test-drug doses were examined. Thus, when subjects were tested with saline vehicle or with low doses of methadone (0.32 mg/kg) or nalbuphine (0.1-0.32 mg/kg), they also received a supplemental dose of 3.2 mg/kg morphine after the final component on that day, before returning to their home cages. Supplemental doses were not administered after higher doses of methadone or nalbuphine to minimize the potential for opioid overdose. Phase 2 lasted 20-25 days.
The third phase began with a gradual increase in the morphine dose administered during the timeout of consecutive daily ICSS sessions. Subjects received 5.6 mg/kg/day morphine for 2 days, followed by 10 mg/kg/day morphine for 2-4 days, followed by the terminal dose of 18 mg/kg/day for the rest of the third phase. The rate of dose escalation was determined individually in each rat to ensure expression of ICSS at a given dose before proceeding to a higher dose, and the only variability in the rate of dose escalation was whether 2, 3, or 4 days were required to complete 10 mg/kg/day treatment and advance to the terminal dose of 18 mg/kg/ day. Once the terminal dose of 18 mg/kg/day morphine was achieved, it was maintained for 7 days. Subsequently, test sessions were resumed, and test drug effects were redetermined using the same dose order and intervals as in the second phase. In addition, the methadone group was also tested with an additional higher dose in phase 3 after testing with the original doses was completed. Also, all subjects were tested with 0.1 mg/kg naltrexone after testing with the designated m agonist was completed. This naltrexone dose was selected as a dose that did not alter ICSS in nondependent rats but that blocked methadone-induced facilitation of ICSS in a previous study (Altarifi et al., 2012) . Subjects in this phase received 18 mg/kg/day morphine on the days that they did not receive the test drug, and 18 mg/kg morphine was also administered at the end of test sessions during which saline vehicle or low methadone (0.32-1.0 mg/kg), or nalbuphine (0.1-3.2 mg/kg) doses were tested. Phase 3 lasted between 20 and 25 days.
At the end of the third phase, daily morphine injections were terminated, but daily ICSS sessions continued for at least 3 days. No further experiments were conducted in the fentanyl group. For the methadone and nalbuphine groups, ICSS sessions and drug treatments were suspended for 2 weeks. Training was then resumed for 3 days, after which an extra phase (phase 4) was conducted in these subjects identical to phase 1.
Drugs
Morphine sulfate, methadone HCl, naltrexone HCl, and fentanyl HCl were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, Maryland, USA). Nalbuphine HCl was provided by Dr Kenner Rice (Chemical Biology Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA). All drugs were dissolved in saline and delivered subcutaneously in a volume of 1 ml/kg body weight.
Data analysis
The primary dependent variable was the reinforcement rate in stimulations/trial during each frequency trial. To normalize these raw data, reinforcement rates from each trial in each rat were converted into percent maximum control rate (%MCR) for that rat. The MCR was determined for each rat during the predrug baseline sessions at the beginning of the experiment. The first component from these sessions (and from all other sessions) was considered to be an acclimation component, and data were discarded. The MCR was defined as the mean of the maximal rates observed during any frequency trial of the second and third components of the three predrug baseline sessions (six total predrug baseline components). Subsequently, %MCR for each trial was calculated as (reinforcement rate during a frequency trialÄMCR) Â 100. Graphs show the mean frequencyrate curves, with brain stimulation frequency on the horizontal axis and ICSS rate expressed as %MCR on the vertical axis.
Frequency-rate curves from test sessions during each phase of the study were submitted for analysis. As noted above, these frequency-rate curves were assessed twice on each test day: once during daily baseline components before that day's injection (and B23 h after the previous day's injection), and again during test components that began 30 min after that day's injection. Daily baseline data and test data from test sessions were analyzed separately. The daily baseline data provided information on changes in baseline ICSS produced by the chronic treatment (saline, 3.2 mg/kg/day morphine, or 18 mg/kg/ day morphine). More specifically, because daily baseline components were conducted B23 h after the most recent injection of the chronic treatment, they provided data on changes in ICSS produced by 23-h withdrawal from that treatment. Because rats in all three test drug groups received the same progression of chronic morphine treatments during sequential phases of the study, daily baseline data from test sessions within each phase were averaged across all rats to yield the mean baseline ICSS data during chronic treatment with saline, 3.2 and 18 mg/kg/day morphine. The mean daily-baseline data during each phase were compared with the predrug baseline data using two-way ANOVA, with the factors phase of chronic treatment and ICSS frequency. A significant ANOVA was followed by a Holm-Sidak posthoc test, and the criterion for significance was set at P less than 0.05. To facilitate within-subject data analysis, data were included only for those rats that completed all three phases of chronic morphine treatment (n = 15, five from each group).
Test data from each test session were analyzed to assess dose effects of each test drug (methadone, fentanyl, nalbuphine) on ICSS frequency-rate curves during each phase of chronic morphine treatment. Within each phase, ICSS test data for a given dose were averaged and compared by two-way ANOVA, with the factors drug dose and ICSS frequency. A similar approach was used to compare the effects of saline and 0.1 mg/kg naltrexone treatment during phase 3. A significant ANOVA was followed by a Holm-Sidak post-hoc test, and the criterion for significance was set at P less than 0.05. Data were included for all rats that completed a given phase. 
Results
Baseline intracranial self-stimulation before and during chronic morphine
During predrug baseline sessions, the mean±SEM MCR for all rats in the study was 57.2±9.8 stimulations per trial, and the mean±SEM control number of total stimulations delivered across all frequencies was 286.7±70.7. The mean±SEM MCR values for the methadone, fentanyl, and nalbuphine groups were 56.5±6.8, 55.8±11.1, and 59.7±12.7, respectively. The mean±SEM control numbers of total stimulations delivered across all frequencies for the methadone, fentanyl, and nalbuphine groups were 282.5±61.9, 263.5±52.6, and 315.5±96, respectively. Figure 1 shows the mean frequency-rate ICSS curves before treatment and during all phases of chronic morphine treatment. During the predrug baseline (i.e. before any drug administration), little responding was maintained by the lower frequencies of stimulation (56-79 Hz) and ICSS increased at the intermediate and higher frequencies (89-158 Hz). Chronic treatment with vehicle and 3.2 mg/kg morphine did not alter ICSS significantly. Treatment with 18 mg/kg/day morphine produced a decrease in ICSS relative to the predrug baseline (significant at 100-126 Hz). ICSS partially recovered within three days after termination of chronic morphine, although the ICSS rates were still significantly decreased at one frequency (112 Hz).
Effects of methadone on intracranial self-stimulation before and during chronic morphine Figure 2 shows the effect of methadone on ICSS. During vehicle treatment, methadone failed to increase ICSS at any brain stimulation frequency. Rather, methadone dose-dependently decreased ICSS maintained by high frequencies of brain stimulation, with significant decreases at 126-158 Hz after 1.0 mg/kg methadone and at 100-158 Hz after 3.2 mg/kg methadone ( Fig. 2a and b ). Lower doses of methadone (0.032-0.1 mg/kg) were also tested, but as with 0.32 mg/kg methadone, they failed to alter ICSS (data not shown). Repeated treatment with 3.2 mg/kg/day morphine ( Fig. 2c and d Fig. 2e and f) . Two subjects died during high-dose morphine treatment; hence, only five rats completed testing with all methadone doses in this phase. Effects of fentanyl on intracranial self-stimulation before and during chronic morphine Figure 3 shows the effect of fentanyl on ICSS. During vehicle treatment, a low dose of 0.003 mg/kg fentanyl increased ICSS at one frequency (89 Hz), but only ratedecreasing effects were produced by higher fentanyl doses of 0.01 mg/kg (158 Hz) and 0.03 mg/kg (100-158 Hz) ( Fig. 3a and b) . A lower fentanyl dose of 0.001 mg/kg was also tested, and it did not alter ICSS (data not shown). During chronic 3.2 mg/kg/day morphine, 0.003 mg/kg fentanyl did not produce any significant change in ICSS compared with vehicle. However, the effects of 0.01 and 0.03 mg/kg fentanyl changed from producing only decreases in ICSS at high frequencies during vehicle treatment to exclusive increases in ICSS at intermediate frequencies during 3.2 mg/kg/day morphine treatment. Thus, fentanyl at 0.01 and 0.03 mg/kg exclusively in-creased ICSS at 89-100 and 71-100 Hz, respectively ( Fig. 3c and d) . A higher fentanyl dose of 0.1 mg/kg was also introduced during this phase, and this dose almost eliminated responding and significantly reduced ICSS at the highest five frequencies (100-158 Hz). One of six rats died during this phase; thus, only five rats completed testing with all fentanyl doses and advanced to the next phase. During treatment with 18 mg/kg/day morphine, neither 0.003 nor 0.01 mg/kg fentanyl altered ICSS at any . 3e and f) .
Effects of nalbuphine on intracranial self-stimulation before and during chronic morphine Figure 4 shows the effects of nalbuphine on ICSS. During vehicle treatment, nalbuphine primarily increased ICSS, although these effects were not monotonically related to dose ( Fig. 4a and b) . Thus, exclusive increases in ICSS were produced by nalbuphine doses of 0.1 mg/kg (79 Hz), 0.32 mg/kg (71-89 Hz), and 3.2 mg/kg (71-89 Hz), and the highest dose of 10 mg/kg produced biphasic effects (increased ICSS at 63-79 Hz and decreased ICSS at 158 Hz). In contrast, 1.0 mg/kg nalbuphine (the first dose tested) did not increase ICSS at any frequency and significantly decreased ICSS at the highest frequency (158 Hz). Repeated treatment with 3.2 mg/kg/day morphine eliminated expression of the rate-decreasing effects of nalbuphine, and enhanced the dose dependence and magnitude of its rate-increasing effects. For example, 10 mg/kg nalbuphine increased ICSS at frequencies of 63-100 Hz and did not decrease ICSS at any frequency ( Fig. 4c and d ). During treatment with 18 mg/ kg/day morphine, nalbuphine produced similar effects consisting of exclusive increases in ICSS across all nalbuphine doses ( Fig. 4e and f) . One of six rats died during treatment with 18 mg/kg/day nalbuphine; thus, only five rats completed testing with all nalbuphine doses in this phase.
Effect of naltrexone on intracranial self-stimulation during chronic 18 mg/kg/day morphine Before termination of treatment with 18 mg/kg/day morphine, 0.1 mg/kg naltrexone was tested, and the results are shown in Fig. 5 . Naltrexone decreased ICSS at frequencies of 112 and 126 Hz.
Effect of methadone and nalbuphine after 3 weeks of morphine abstinence
The effects of methadone (n = 5) and nalbuphine (n = 5) were redetermined, beginning after 3 weeks of morphine abstinence. As noted above, daily baseline ICSS recovered toward predrug baseline levels within 3 days after termination of morphine treatment (Fig. 1) , and daily baseline ICSS persisted at predrug baseline levels throughout testing during abstinence. For example, for the 10 rats that completed abstinence testing, the predrug control±SEM number of stimulations per component was 297.8±83.6, and the mean number of stimulations per component during abstinence testing was 293.0±163.0. Figure 6 shows that the effects of methadone and nalbuphine during abstinence testing were generally similar to their effects during treatment with 3.2 mg/kg/day morphine. Thus, 0.32 mg/kg methadone did not significantly alter ICSS, 1.0 mg/kg methadone increased ICSS at intermediate frequencies (63-100 Hz), and 3.2 mg/kg methadone tended to produce biphasic effects, with increased ICSS at 71-79 Hz and a nonsignificant decrease in the mean ICSS rates at high frequencies (126-158 Hz) ( Fig. 6a and b) . Similarly, nalbuphine produced dose-dependent increases in ICSS, although the effects of the lowest dose of nalbuphine (0.1 mg/kg) did not achieve statistical significance ( Fig. 6c and d) .
Discussion
This study examined the impact of graded morphine exposure on the changes in ICSS produced by agonists with high efficacy (methadone), intermediate efficacy (fentanyl), or low efficacy (nalbuphine) at m-opioid receptors. There were three main findings. First, in agreement with previous results (Altarifi et al., 2012) , the higher efficacy m agonists methadone and fentanyl produced primarily rate-decreasing effects in opioid-naive subjects, whereas the low-efficacy m agonist nalbuphine produced primarily rate-increasing effects that did not vary systematically as a function of dose. Second, repeated morphine produced cross-tolerance to the rate-decreasing effects and enhanced expression of the rate-increasing effects of all three m agonists. Finally, the daily morphine dosing regimen used here produced withdrawal-associated decreases in baseline ICSS determined B23 h after morphine. Repeated morphine also enhanced the ratedecreasing effects of the antagonist naltrexone. However, this evidence of opioid dependence and withdrawal was not sufficient to account for enhanced expression of m agonist-induced rate-increasing effects. Taken together, these results provide further evidence to suggest that repeated opioid exposure increases the degree to which m agonists produce abuse-related facilitation of ICSS.
Opioid effects in opioid-naive rats
The constellation of rate-increasing and rate-decreasing effects produced in this study by methadone, fentanyl, and nalbuphine in opioid-naive subjects agrees with the effects reported previously for these and other m agonists that vary in efficacy at m receptors (Altarifi and Negus, 2011; Altarifi et al., 2012) . Specifically, rate-decreasing effects predominated for high-efficacy agonists; lower efficacy agonists produced weaker and more variable ratedecreasing effects; and antagonists such as naltrexone failed to alter ICSS at doses that antagonize the effects of m agonists. The efficacy-dependent rate-decreasing effects of m agonists in this ICSS procedure agree with the efficacy-dependent magnitude and/or variability in the rate-decreasing effects of m agonists in other assays of responding maintained by other reinforcers (e.g. food) under other schedules (Oliveto et al., 1991; Pitts et al., 1996) . Moreover, in the ICSS literature, drug-induced facilitation of ICSS is often interpreted as evidence of an abuse-related effect, whereas drug-induced depression of ICSS is often interpreted as evidence of abuse-limiting dysphoric effects or motor impairment (Carlezon and Chartoff, 2007; Bauer et al., 2013) . From this perspective, the present results could be interpreted to suggest that abuse-limiting dysphoric and/or motor effects often predominate over abuse-related rewarding effects of m agonists in opioid-naive rats. This finding in ICSS may be related to the observation that m agonists are often more efficacious in producing dysphoric subjective effects and behavioral impairment than abuse-related euphoric effects in opioid-naïve/inexperienced human participants (Lasagna et al., 1955; Walker et al., 2001) Opioid effects in morphine-treated rats Repeated morphine has been shown previously to produce tolerance to the ICSS-decreasing effects of morphine (Lorens and Mitchell, 1973; Altarifi and Negus, 2011) , and the present study found that repeated morphine also produced cross-tolerance to the ICSSdecreasing effects of the other m agonists methadone and fentanyl. This is in agreement with previous reports of morphine-induced cross-tolerance to other effects of methadone and/or fentanyl, including their rate-decreasing effects in assays of schedule-controlled responding for food reinforcement Hughes et al., 1995; Smith et al., 1997) or their morphine-like discriminative stimulus effects (Young et al., 1991a (Young et al., , 1991b Walker et al., 1997) . Nalbuphine produced only small and inconsistent rate-decreasing effects before morphine treatment, and as a result, cross-tolerance was difficult to assess. Nonetheless, the complete absence of nalbuphine-induced rate-decreasing effects during morphine treatment suggests that morphine also produced cross-tolerance to any rate-decreasing effects of nalbuphine. Previous studies have failed to reveal crosstolerance between the rate-decreasing effects of morphine and nalbuphine in assays of schedule-controlled responding for food (Oliveto et al., 1991; Picker and Yarbrough, 1991; Smith et al., 1997) , but rate-decreasing effects of nalbuphine in these studies occurred only at high doses, were variable across subjects, and may have been associated with precipitated withdrawal during morphine treatment (see below). The present findings agree with previous reports of cross-tolerance between other effects of morphine and nalbuphine, such as discriminative stimulus effects (Walker et al., 1997) and thermal antinociceptive effects (Gringauz et al., 2001) .
In addition to producing tolerance to m agonist-induced rate-decreasing effects, repeated morphine treatment also enhanced the expression of m agonist-induced facilitation of ICSS. This is in agreement with previous studies reporting that repeated morphine enhances the expression of its own ICSS-facilitating effects (Carlezon and Wise, 1993; Altarifi et al., 2012) , and extends this phenomenon to other m agonists with a broad range of efficacies at m receptors. There are at least two possible explanations for the enhanced expression of abuse-related rate-increasing effects of m agonists during morphine treatment. First, m agonist effects on ICSS may reflect an integration of rate-increasing and rate-decreasing effects, and repeated morphine may produce selectively greater tolerance to rate-decreasing effects and unmask enhanced expression of rate-increasing effects. In support of this possibility, a previous study using targeted intracranial drug injections found that different brain areas mediate morphine-induced rate-increasing effects (forebrain areas proximal to the striatum) and ratedecreasing effects (brain stem areas proximal to the periaqueductal gray) (Broekkamp et al., 1976) , and other studies reported that chronic morphine produces greater m receptor desensitization in areas that mediate ratedecreasing effects (Sim et al., 1996) . Alternatively, or additionally, repeated morphine may produce sensitization to neural substrates that mediate rate-increasing effects. For example, repeated morphine produced sensitization to morphine-induced increases in mesolimbic dopamine release in the nucleus accumbens (Spanagel and Shippenberg, 1993) . Irrespective of the underlying mechanism, these data suggest a shift in morphine effects that favors the expression of abuserelated rate-increasing effects relative to abuse-limiting rate-decreasing effects. This shift apparent in ICSS may be related to the finding that regimens of m-agonist exposure can also increase the expression of abuse-related rewarding effects in preclinical assays of place conditioning (Lett, 1989; Shippenberg et al., 1996) , increase reinforcing effects in preclinical assays of self-administration (Thompson and Schuster, 1964; Yanagita, 1978; Carrera et al., 1999; Negus and Rice, 2009) , and increase the expression of abuse-related subjective effects and reinforcing effects in humans (Comer et al., 2010; Cooper et al., 2012) .
The regimen of repeated morphine treatment used in this study produced little evidence of tolerance to m agonist-induced ICSS facilitation, even when the daily morphine dose was increased to 18 mg/kg/day. For example, the low-efficacy m agonist nalbuphine produced the greatest and most reliable facilitation of ICSS during vehicle treatment, and it continued to produce equivalent or greater facilitation of ICSS during morphine treatment. It is possible that more intensive treatment regimens (e.g. more frequent morphine dosing or longer treatment times) may have produced tolerance to rate-increasing effects, but the present results suggest that m agonist-induced facilitation of ICSS is relatively resistant to tolerance.
Facilitation of ICSS has been interpreted as an abuserelated drug effect (Wise, 1998; Carlezon and Chartoff, 2007; Vlachou and Markou, 2010) . In agreement with this proposition, we reported recently that the overall magnitude of ICSS facilitation produced in rats by a series of monoamine releasers correlated with another, more extensively validated measure of abuse liability: progressive-ratio measures of reinforcement in drug selfadministration procedures in nonhuman primates (Bauer et al., 2013) . However, the present results with different efficacy m agonists do not align so clearly with findings from nonhuman primate drug self-administration results. Specifically, facilitation of ICSS by nalbuphine was similar to or greater than facilitation produced by methadone or fentanyl across morphine treatment regimens in the present study, but in drug self-administration studies in nonhuman primates, the reinforcing effects of nalbuphine were weaker than those of the higher efficacy m agonist alfentanil (Hursh and Winger, 1995; Rowlett et al., 2002) . Future studies will be required to clarify the relationship between ICSS and drug self-administration measures of opioid abuse liability.
Role of morphine dependence and withdrawal
Treatment with the highest daily morphine dose (18 mg/kg/day) produced evidence of morphine dependence in this study, insofar as ICSS was depressed at a time of spontaneous withdrawal (23 h after each daily dose). Moreover, this withdrawal-associated depression of ICSS could be reversed by all three m agonists and exacerbated by treatment with the m-opioid antagonist naltrexone. These findings are in agreement with previous studies showing that similar morphine treatment regimens can produce signs of opioid dependence (Kishioka et al., 1996) and that depression of ICSS is one sign of opioid withdrawal (Easterling and Holtzman, 1997; Liu et al., 2008; Altarifi and Negus, 2011) . However, three findings suggest that enhanced expression of m agonist-induced ICSS facilitation could not be attributed completely to reversal of morphine withdrawal. First, this enhanced expression of ICSS facilitation was observed during treatment with a lower dose of 3.2 mg/kg/day morphine, which did not produce evidence of dependence or withdrawal. Second, during treatment with 18 mg/kg/day morphine, nalbuphine reliably facilitated ICSS despite the informal observation in all rats that it precipitated diarrhea, a common sign of opioid withdrawal. m-Opioid agonist effects on ICSS Altarifi et al. 469 Finally, the enhanced expression of methadone-induced and nalbuphine-induced facilitation of ICSS was also observed more than 2 weeks after the termination of repeated morphine, a time when diarrhea was no longer evident.
